ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Total Liabilities : $38.95 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Total Liabilities?

ASLAN Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $38.95 Mil.

ASLAN Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 ($45.52 Mil) to Dec. 2023 ($37.91 Mil) but then increased from Dec. 2023 ($37.91 Mil) to Mar. 2024 ($38.95 Mil).

ASLAN Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($37.21 Mil) to Dec. 2022 ($52.82 Mil) but then declined from Dec. 2022 ($52.82 Mil) to Dec. 2023 ($37.91 Mil).

ASLAN Pharmaceuticals Total Liabilities Historical Data

The historical data trend for ASLAN Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals Total Liabilities Chart

ASLAN Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

23.95

26.23

37.21

52.82

37.91

ASLAN Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															50.43	48.84	45.52	37.91	38.95

ASLAN Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ASLAN Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13.115	+	(24.799	+	-0.0010000000000048
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	37.91

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	24.627	-	-13.287
	=	37.91

ASLAN Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.604	+	(19.35	+	-0.00099999999999767
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	38.95

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	20.988	-	-17.965
	=	38.95

ASLAN Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190

Website

https://www.aslanpharma.com

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.